Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02164929
Recruitment Status : Terminated (Poor recruitment)
First Posted : June 17, 2014
Results First Posted : September 25, 2017
Last Update Posted : September 25, 2017
Sponsor:
Information provided by (Responsible Party):
Duke University

Brief Summary:
The purpose of this study is to assess the effectiveness of transversus abdominal plane (TAP) block, thoracic epidural or paravertebral block (PVB) for controlling postoperative pain when compared with opioid you self-administer in your vein using a PCA device. The primary outcome will be postoperative opioid consumption within 24 hours after surgery. A total of 120 subjects will be randomized in a 1:1:1:1 ratio to receive a TAP block, PVB, TEA or no block (PCA alone).Patients in all groups will be cared for using an established enhanced recovery after surgery (ERAS) pathway incorporating a multimodal analgesic regimen using IV acetaminophen and postoperative PCA fentanyl.

Condition or disease Intervention/treatment Phase
Laparoscopic Colorectal Resection Procedure: TAP block Procedure: Epidural Procedure: Paravertebral block Drug: Acetaminophen 1g IV Drug: Dexamethasone 4mg Drug: Midazolam up to 2mg Drug: Propofol 1-2.5 mg/kg Drug: Sevoflurane to keep a bispectral index of between 40-60 Drug: Local infiltration with 10 mL of plain ropivacaine 0.25% Drug: Lidocaine Drug: Epinephrine Drug: Hydromorphone Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Single-Blind Study to Evaluate the Efficacy of Transversus Abdominis Plane Versus Paravertebral Regional Blockade in Patients Undergoing Laparoscopic Colectomy
Study Start Date : December 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Arm Intervention/treatment
Active Comparator: Paravertebral block
Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
Procedure: Paravertebral block
Other Name: PVB

Drug: Acetaminophen 1g IV
Drug: Dexamethasone 4mg
Drug: Midazolam up to 2mg
Drug: Propofol 1-2.5 mg/kg
Drug: Sevoflurane to keep a bispectral index of between 40-60
Drug: Local infiltration with 10 mL of plain ropivacaine 0.25%
Active Comparator: TAP block
Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
Procedure: TAP block
Other Name: Transversus abdominus plane block

Drug: Acetaminophen 1g IV
Drug: Dexamethasone 4mg
Drug: Midazolam up to 2mg
Drug: Propofol 1-2.5 mg/kg
Drug: Sevoflurane to keep a bispectral index of between 40-60
Drug: Local infiltration with 10 mL of plain ropivacaine 0.25%
Active Comparator: Epidural

An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).

A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements.

Procedure: Epidural
Other Name: Thoracic Epidural Anesthesia (TEA)

Drug: Acetaminophen 1g IV
Drug: Dexamethasone 4mg
Drug: Midazolam up to 2mg
Drug: Propofol 1-2.5 mg/kg
Drug: Sevoflurane to keep a bispectral index of between 40-60
Drug: Local infiltration with 10 mL of plain ropivacaine 0.25%
Drug: Lidocaine
1.5% lidocaine

Drug: Epinephrine
1:200,000 epinephrine

Drug: Hydromorphone
400-800 mcg Hydromorphone will be given preoperatively

Active Comparator: No block (PCA alone)
Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
Drug: Acetaminophen 1g IV
Drug: Dexamethasone 4mg
Drug: Midazolam up to 2mg
Drug: Propofol 1-2.5 mg/kg
Drug: Sevoflurane to keep a bispectral index of between 40-60
Drug: Local infiltration with 10 mL of plain ropivacaine 0.25%



Primary Outcome Measures :
  1. Postoperative Opioid Consumption [ Time Frame: 24 hours after surgery ]
    If opioid other than fentanyl is used, the dose will be converted to morphine equivalent.


Secondary Outcome Measures :
  1. Pain Scores [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
    Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where "0" represents no pain and "10" represents worst pain ever, at 30, 60, 90, 120 min and every 6 hours for 24 hours and every 12 hours for 48 hours and once a day thereafter until discharge. Data were collected at the indicated time points and an average pain score was calculated.

  2. Quality of Recovery [ Time Frame: 72 hours ]
    Quality of Recovery Score (QoR-15) is measured on a scale of 0-150 (0=poor, 150 = excellent). Scores were collected daily for 72 hours and then averaged.

  3. Complications as Measured by a Modified Postoperative Morbidity Survey (MPMS) [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
    Complications using a Modified Postoperative Morbidity Survey (MPMS)

  4. Time to First Bowel Movement [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
  5. Opioid Related Side Effects [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
    Occurrence and duration of opioid related adverse events including postoperative nausea and vomiting (PONV); pruritus, urinary retention, confusion, sedation and respiratory depression at the above time points.

  6. Time to First Ingestion of Solid Food [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
  7. Number of Epidural-related Side Effects [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]
  8. Length of Stay [ Time Frame: Participants will be followed for the duration of hospital stay, an estimated 1 week ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male or female, ≥ 18 years of age
  • Patients scheduled to undergo laparoscopic colectomy without stoma under general anesthesia
  • American Society of Anesthesiology (ASA) Physical Class 1-3.

Exclusion Criteria:

  • Open colectomy
  • Perineal resection
  • Stoma formation
  • Patients with a contraindication to TEA or regional anesthesia.
  • Pregnancy, nursing, or planning to become pregnant during the study or within one month.
  • Long-acting opioid medication within 3 days.
  • Any opioid medication within 24 hours.
  • Body weight less than 50 kilograms (~110 pounds)
  • Uncontrolled anxiety, schizophrenia, or other psychiatric disorder
  • Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
  • Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  • Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02164929


Locations
Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27701
Sponsors and Collaborators
Duke University

Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT02164929    
Other Study ID Numbers: Pro00047810
First Posted: June 17, 2014    Key Record Dates
Results First Posted: September 25, 2017
Last Update Posted: September 25, 2017
Last Verified: January 2017
Keywords provided by Duke University:
TAP block
Paravertebral block
Epidural
Laparoscopic colectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Acetaminophen
Dexamethasone
Lidocaine
Epinephrine
Racepinephrine
Midazolam
Hydromorphone
Anesthetics
Propofol
Ropivacaine
Sevoflurane
Epinephryl borate
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Anesthetics, Local
Sensory System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers